Takeda preps another drug auction as execs look to further trim its post-Shire buyout debt load — report
Takeda is polishing up another piece of the drug portfolio for auction as it looks to whittle down the big debt it took on to buy Shire.
After selling off Xiidra to Novartis for $5.3 billion, Reuters now reports Takeda has a slate of OTC and prescription drugs in Europe it’s packaged together and priced at a hopeful $1.7 billion. Earnings ahead of EBITDA are 160 million euros a year, so the range is just over 10X.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.